Novartis and Sun agreed generic Gleevec won't surface until February 2016.
Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.
Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.
The company's guidance aligns with expectations that 2014 will be a nail-biter.
The company says it is moving its Januvia sales pitch from defending market share to expanding it.
BMS is showing signs of emerging from the cliff, but doubt lingers on Eliquis's slow launch in a post-Plavix marketplace.
Researchers say it's not just payers supporting the switch, and all ages appear to be brand agnostic.
The generics giant said it will lay off about 5,000 employees as it braces for the expiry of one of its specialty brands.
The generics maker says it may take five years for its iteration of the GSK asthma/COPD brand to hit the market.
The CEO says Sanofi's patent-loss turnaround is coming.
Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.
The advisory panel endorsed the treatment with an 11-2 vote.
FDA draft guidance for generic Advair hits GSK's stock; US looks into GSK's China conduct; Roche invests in cancer and hep. B research; Biogen inks a Parkinson's partnership; Forest names former B&L chief as CEO
The positive way to frame the companies' quarterly results: "less bad," as generics continued to plague their balance sheets.
The drug maker added biotechs Optimer and Trius to the fold, a bid to dominate in hard-to-treat infections.
Sales slid 9% during the second quarter, with generic Avapro and Plavix inflicting financial pain. The company says it is going to invest more to promote Eliquis among HCPs and plans on deploying a wider diabetes sales force.
The Indiana drug maker logged a 6% sales increase over the same period last year. Higher prices were responsible for the majority of the growth.
GlaxoSmithKline second-quarter sales rose 2% over the same period last year. CEO Andrew Witty says it is too early to tally the impact of China's corruption allegations.
The healthcare reform information campaign continues; J&J settles a shareholder lawsuit; Eli Lilly freezes company salaries; and Quest dumps cancer med royalty rights.
Amgen pays $50 million for a cardio collaboration, and Wockhardt gets locked out of the EU.
The FDA's priority review for the Phase III chronic lymphocytic leukemia drug comes on top of Breakthrough Therapy designation, which the agent won in May.
CHMP recommended two Remicade biosimilars for approval. Its nod comes with an added shakeup: the European agency sanctioned the copies for indications beyond RA.
The effectiveness of new drugs is in decline, says an analysis, and researchers say comparative studies should look beyond efficacy measures.
The drug maker eases the burden on its Symbicort franchise by scooping up Pearl for $510 million.
AbbVie lays off 100 R&D staff; Teva looks to expand Copaxone footprint; researchers crack HIV protein code; monitors may be misleading diabetics and a prototype sensor turns iPhones into virus hunters.
Pfizer cuts 136 workers loose in Ireland, BMS is investing in heart failure treatments, CMS has an official new leader, and Sanofi's iBGStar may have a competitor.
Two studies released show that the story behind lower consumer healthspend isn't about generics improving health.
Baxter's Alzheimer's treatment is out of the running; Eli Lilly has upped its layoffs; insured consumers are spending less on healthcare; stains and prostate cancer may have an amicable relationship; doctors aren't screening teens for HIV.
Sales fell more sharply during the quarter than execs expected, and Merck said it has put more Januvia-only reps behind its diabetes franchise.
Sales slipped 9% during the quarter, compared to the same period last year, but analysts zeroed in on if and when the company will split and how arthritis pill Xeljanz will tackle Europe.